Evidence map›Paper›PMID 32269687›Full record

ArticleInternational journal of clinical and experimental pathology2020

Vimentin immunoexpression is associated with higher tumor grade, metastasis, and shorter survival in colorectal cancer.

Jaudah Al-Maghrabi

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Biomarker Potential of Vimentin in Oral Cancers.Life (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Jaudah Al-MaghrabiDepartment of Pathology, Faculty of Medicine, King Abdulaziz University Jeddah, Saudi Arabia.
King Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe association between vimentin immunoexpression and poor prognosis has been described in many human cancers. The objective of this study was to evaluate the relationship between vimentin immunostaining and colorectal carcinoma (CRC) clinicopathologic parameters. MATERIALS AND

methodsSamples included 202 primary CRC tissues, 41 adenomas and 37 normal colonic mucosae. Anti-Vimentin (V9) monoclonal antibody was used for immunohistochemical staining. Vimentin expression was evaluated based on the percentage of cytoplasmic expression in epithelial cells.

resultsVimentin expression was identified in 35 (17.3%) of CRC samples. All normal mucosa and adenoma samples were vimentin negative. There was an association between positive vimentin immunostaining and high tumor grade, distant metastasis, and short overall (Log rank 5.112, P=0.024), as well as disease-free survival probabilities (Log rank 6.173, P=0.013). There was no association between vimentin expression and age, gender, tumor location, tumor size, tumor stage, nodal involvement, lymphovascular invasion, margin status, or tumor recurrence.

conclusionVimentin immunoexpression is associated with worse prognosis in CRC patients. Vimentin can be considered a potentially important disease biomarker and could be a target for CRC therapy.

Indexed as

Vimentin immunoexpression colorectal survival

Identifiers

PMID32269687
PMCPMC7137029
OpenAlexW3021619834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.